Pasithea Therapeutics Faces Negative Stock Momentum Despite Positive Phase 1 Data

Pasithea Therapeutics shares are trading lower after the company reported mixed reactions to its positive interim Phase 1 data for PAS-004, resulting in investor caution due to the forward-looking uncertainties discussed in their press release.